Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY

被引：0
|
作者：
Nixon, R.
Eckert, B.
Cutter, G.
Mercier, F.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Novartis Inst Biomed Res Inc, Cambridge, MA USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [21] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [22] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217
  • [23] Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis in real world clinical practice
    Totaro, R.
    Costantino, G.
    Bellantonio, P.
    Danni, M.
    Di Carmine, C.
    Fantozzi, R.
    Cerqua, R.
    Fuiani, A.
    Mundi, C.
    Ruggieri, S.
    Marini, C.
    Provinciali, L.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 267 - 267
  • [24] Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden
    O'Day, Ken
    Meyer, Kellie
    Stafkey-Mailey, Dana
    Watson, Crystal
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 295 - 302
  • [25] Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Terzi, Murat
    Ozer, Bilge
    Turkoglu, Recai
    Karabudak, Rana
    Efendi, Husnu
    Soysal, Aysun
    Sevim, Serhan
    Altintas, Ayse
    Kurne, Asli
    Akcali, Aylin
    Akman, Gulsen
    Yuceyar, Nur
    Balci, Belgin Petek
    Ekmekci, Ozgul
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Altunrende, Burcu
    Turan, Omer Faruk
    GozubatikCelik, Gokcen
    Kale, Nilufer
    Koseoglu, Mesrure
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [26] Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
    Algahtani, Hussein
    Shirah, Bader
    Abobaker, Hind
    Alghanaim, Nebras
    Kamel, Fatemah
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (06) : 199 - 201
  • [27] Oral fingolimod versus natalizumab on measures of disease-freedom: indirect comparison of results from FREEDOMS and AFFIRM studies
    Nixon, R.
    Bergvall, N.
    Sfikas, N.
    Chin, P.
    Tomic, D.
    Cutter, G.
    JOURNAL OF NEUROLOGY, 2013, 260 : S125 - S125
  • [28] The effect of cladribine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis
    Cellerino, M.
    Sirito, T.
    Schiavi, S.
    Tazza, F.
    Pierella, C.
    Boccia, D.
    Mancuso, E.
    Boffa, G.
    Capello, E.
    Lapucci, C.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 850 - 850
  • [29] Oral laquinimod for treatment of relapsing-remitting multiple sclerosis
    Weiner, Howard L.
    LANCET NEUROLOGY, 2008, 7 (08): : 672 - 673
  • [30] Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
    Murphy, Julie A.
    Harris, Jacklyn A.
    Crannage, Andrew J.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 619 - 625
12345